Propanc Engages Two Advisory Firms to Identify Strategic Partnering

Maxim Group LLC and Partner International Inc. to Initiate Licensing
Discussions for the Company’s Lead Product, PRP

PR Newswire

MELBOURNE, Australia, May 31, 2016

MELBOURNE, Australia, May 31, 2016 /PRNewswire/ — Propanc Health Group
Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare
company focusing on development of new and proprietary treatments for cancer
patients suffering from solid tumors such as pancreatic, ovarian and
colorectal cancers, today announced that the Company has engaged the services
of Maxim Group LLC and Partner International Inc. to initiate potential
strategic partnering discussions for the Company’s lead product, PRP.

Propanc Health Group Logo

PRP, a combination of two proenzymes trypsinogen and chymotrypsinogen, is a
novel, targeted therapy for the treatment and prevention of metastatic
cancer.  Scientific evidence has shown potent effects against cancer stem
cells, inducing these cells to differentiate (transform) into a less
malignant, or dormant state, thus rendering them benign.  Cancer stems cells
represent the final frontier, as they are responsible for metastasis and
invasion, causing the cancer to return and spread.  They are also resistant to
standard treatment options.

“Our lead product, PRP, represents an exciting and novel method to control the
threat of resistant tumors which if left untreated, can ultimately lead to
patient death,” said James Nathanielsz, Propanc’s Chief Executive Officer.
“What is also important, is that PRP targets cancer stem cells, but leaves
healthy stem cells alone.  This means it is less toxic than standard
treatments.  We believe PRP could become a welcome addition to the treatment
process for many aggressive cancer types, like pancreatic and ovarian cancers,
where patient prognosis is often poor, when diagnosed.  We therefore think
this will be an attractive, novel therapy for those Pharmaceutical, Biotech or
Mid-Tier Specialty Companies serious about treating this killer disease.”

Maxim Group LLC is a leading full-service investment banking, securities and
wealth management firm headquartered in New York. The Firm provides a full
array of financial services including investment banking; private wealth
management; and global institutional equity, fixed income and derivative sales
& trading, equity research and prime brokerage services to a diverse range of
corporate clients, institutional investors and high net worth individuals.

Partner International is a leading corporate development firm with offices in
the US, Canada, Australia and Switzerland, whose highly experienced team with
all therapeutic areas, including drugs, diagnostics, vaccines and medical
devices, has led to both buy- and sell-side transactions in markets around the
world. President and CEO, Joanne Ball-Gautschi said “We are very pleased to be
representing Propanc. PRP is a very exciting breakthrough in cancer
therapeutics and we expect significant response from the industry.”

The Company aims to fast track the development of proenzyme related oncology
products into clinical trials initially for pancreatic and ovarian cancers,
followed by colorectal cancer. According to Global Analyst Reports, the
combined world market for pancreatic, ovarian and colorectal cancers are
expected to reach over $12 billion by 2020.

About Propanc:    
Propanc is developing new cancer treatments for patients suffering from
pancreatic, ovarian and colorectal cancers. We have developed a formulation of
anti-cancer compounds, which exert a number of effects designed to control or
prevent tumors from recurring and spreading throughout the body. Our products
involve or employ pancreatic proenzymes, which are inactive precursors of

In the near term, we intend to target patients with limited remaining
therapeutic options for the treatment of solid tumors. In future, we intend to
develop our lead product to treat (i) early stage cancer and (ii)
pre-cancerous diseases and (iii) as a preventative measure for patients at
risk of developing cancer based on genetic screening.  For more information,

Forward-looking Statements:   
Certain of the matters discussed in this announcement involve risks and
uncertainties  including, without limitation, those regarding the Company’s
ability to establish and maintain the proprietary nature of its  technology
through the patent process, its ability to license from others patents and
patent applications, if necessary, to develop certain products, its ability to
implement its long range business plan for various applications of its
technology, and its ability to enter into agreements with any necessary
marketing and/or distribution partners for purposes of commercialization. This
is not a solicitation to buy or sell securities and does not purport to be an
analysis of the company’s financial position.  See Propanc’s most recent
Quarterly Report on Form 10-Q and related 8K filings.

Logo –

To view the original version on PR Newswire,

SOURCE Propanc Health Group Corporation

Contact: Stanley Wunderlich, Consulting for Strategic Growth 1 Ltd, CEO,
800-625-2236 ext. 7770,,